Expected change: a new concept for monitoring patients on oral bisphosphonates

It is essential to closely monitor the response to oral bisphosphonate therapy for osteoporosis, as many patients are nonadherent. The conventional approach is to monitor whether changes in BMD or bone turnover markers exceed the least significant change. That approach assumed that if a patient were not receiving a treatment, there would be no change in the BMD. We propose an alternative approach, that of expected change. We define this expected change as the change in bone mineral density (BMD) (at 24 months) or bone turnover markers (at three months) that is exceeded in 90% of patients who are adherent with oral bisphosphonate therapy. We studied 108 postmenopausal women (age<85 years) who were randomised to the licensed dose of alendronate, ibandronate or risedronate treatment for two years, along with calcium and vitamin D supplementation. We identified the performance of BMD and bone turnover markers in three ways. We calculated the signal-to-noise ratio, which was lower for BMD [4.1 and 2.1 for lumbar spine BMD (LSBMD) and total hip BMD (THBMD), respectively] compared to bone turnover markers (9.4 and 10.2 for CTX and PINP, respectively). We estimated the response rate as the percentage of women exceeding the least significant change, which was lower for BMD (47% and 24% for LSBMD and THBMD, respectively) than for bone turnover markers (96% and 94% for CTX and PINP, respectively). We estimated the expected change as the 90th (or 10th) percentile of change in adherent patients. We required the expected change to exceed the least significant change, and this was not observed for LS- and THBMD, but it was observed for CTX and PINP (expected changes of 0.233 ng/mL and 12.1 ng/mL, respectively). Thus, the bone turnover markers CTX and PINP showed the best performance as response markers for monitoring oral bisphosphonate treatment, and the new approach is based on a biological rather than a statistical endpoint when using the expected change approach.

Authors

Institutions

Publication Details

Journal
Journal of Bone and Mineral Research
Published
2026-02-22
DOI
https://doi.org/10.1093/jbmr/zjag039
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expected change: a new concept for monitoring patients on oral bisphosphonates

Stephen Cummings, Marian Schini, Richard Eastell, Margaret A Paggiosi et al.
Journal of Bone and Mineral Research
Bone health and osteoporosis research
article

Expected change: a new concept for monitoring patients on oral bisphosphonates

Stephen Cummings, Marian Schini, Richard Eastell, Margaret A Paggiosi, Fatma Gossiel
article en

Abstract

It is essential to closely monitor the response to oral bisphosphonate therapy for osteoporosis, as many patients are nonadherent. The conventional approach is to monitor whether changes in BMD or bone turnover markers exceed the least significant change. That approach assumed that if a patient were not receiving a treatment, there would be no change in the BMD. We propose an alternative approach, that of expected change. We define this expected change as the change in bone mineral density (BMD) (at 24 months) or bone turnover markers (at three months) that is exceeded in 90% of patients who are adherent with oral bisphosphonate therapy. We studied 108 postmenopausal women (age<85 years) who were randomised to the licensed dose of alendronate, ibandronate or risedronate treatment for two years, along with calcium and vitamin D supplementation. We identified the performance of BMD and bone turnover markers in three ways. We calculated the signal-to-noise ratio, which was lower for BMD [4.1 and 2.1 for lumbar spine BMD (LSBMD) and total hip BMD (THBMD), respectively] compared to bone turnover markers (9.4 and 10.2 for CTX and PINP, respectively). We estimated the response rate as the percentage of women exceeding the least significant change, which was lower for BMD (47% and 24% for LSBMD and THBMD, respectively) than for bone turnover markers (96% and 94% for CTX and PINP, respectively). We estimated the expected change as the 90th (or 10th) percentile of change in adherent patients. We required the expected change to exceed the least significant change, and this was not observed for LS- and THBMD, but it was observed for CTX and PINP (expected changes of 0.233 ng/mL and 12.1 ng/mL, respectively). Thus, the bone turnover markers CTX and PINP showed the best performance as response markers for monitoring oral bisphosphonate treatment, and the new approach is based on a biological rather than a statistical endpoint when using the expected change approach.

Journal of Bone and Mineral Research
The Coordinating Center (US), University of Sheffield (GB)
Amgen, Alexion Pharmaceuticals, Versus Arthritis, Samsung, Medical Research Council
Good health and well-being
Openalex Percentile: Top 47%
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.